Abstract
The novel corona virus, previously dubbed 2019-nCoV and now officially
named SARS-CoV-2 and COVID-19 has caused major outbreaks of deadly
pneumonia in the 21st century has began in Wuhan, China in late 2019 and
now become a destructive to global health and therefore the utmost need
of the hour is to develop therapeutic candidates or vaccines against it
(Zhu et al., 2020). Numerous corona viruses, first discovered in
domestic poultry in the 1930s, 2002 and 2012 cause respiratory,
gastrointestinal, liver, and neurologic diseases in animals. Only 7
corona viruses are known to cause disease in humans. There is an urgent
need to identify specific targets to design promising therapeutic agents
against severe acute respiratory syndrome coronavirus aetiological agent
of coronavirus disease 2019 (COVID-19) characterised by pulmonary
infection in humans. The need exists for additional treatment options
addressing antiviral replication, and against SARS-CoV-2. Virus entry
and replication strategies are potential targets for antiviral drug
treatments. Since NF-κB pathway is often targeted by viral pathogens to
enhance viral replication, host cell survival and host immune evasion.
Viruses may activate or suppress NF-kB. (Marta et al., 2014). There have
many studies on SARS-COV since 2002-2003 SARS epidemics. SARS-COV2
(COVID-19) belongs to the same family of corona viruses and shares many
similarities (3), including SARS-CoV-1. Here we discuss the possible
mechanisms of NFκB inhibitor interference with the SARS-CoV-2
replication cycle.